| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Tuesday’s Close |
|---|---|---|---|---|---|
| NVS | Novartis AG | $85.13 | $197.65B | N/A |
NVS or NVO: Which Is the Better Value Stock Right Now?
http://www.zacks.com/stock/news/431571/nvs-or-nvo-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-431571
Jun 19, 2019 - NVS vs. NVO: Which Stock Is the Better Value Option?
0
Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status
http://www.zacks.com/stock/news/431105/jazzs-jazz-new-sleep-drug-sunosi-gets-schedule-iv-status?cid=CS-ZC-FT-431105
Jun 18, 2019 - Jazz Pharmaceuticals' (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug Enforcement Agency.
0
Roche's Rozlytrek Gets Approval in Japan for Solid Tumors
http://www.zacks.com/stock/news/431013/roches-rozlytrek-gets-approval-in-japan-for-solid-tumors?cid=CS-ZC-FT-431013
Jun 18, 2019 - Roche's (RHHBY) oncology portfolio gets a boost with the approval of Rozlytrek for neurotrophic tyrosine receptor kinase fusion-positive, advanced recurrent solid tumors.
0
Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz
http://www.zacks.com/stock/news/430687/novartis-nvs-announces-promising-data-on-tasigna-hyrimoz?cid=CS-ZC-FT-430687
Jun 17, 2019 - Novartis (NVS) announces positive data on CML drugs and biosimilar Hyrimoz.
0
Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris
http://www.zacks.com/stock/news/429338/roche-reports-positive-data-on-rituxan-for-pemphigus-vulgaris?cid=CS-ZC-FT-429338
Jun 13, 2019 - Roche (RHHBY) announces positive data on rheumatic diseases drug, Rituxan, for pemphigus vulgaris.
0
Top Analyst Reports for Visa, Netflix & Accenture
http://www.zacks.com/research-daily/429094/top-analyst-reports-for-visa-netflix-accenture?cid=CS-ZC-FT-429094
Jun 13, 2019 - Top Analyst Reports for Visa, Netflix & Accenture
0
Elastic Nv (ESTC) CEO and Chairman Shay Banon Sold $15.9 million of Shares
http://www.gurufocus.com/news/893420/elastic-nv-estc-ceo-and-chairman-shay-banon-sold-159-million-of-shares
Jun 12, 2019 - Elastic Nv (ESTC) CEO and Chairman Shay Banon Sold $15.9 million of Shares, Stocks: ESTC, release date:Jun 12, 2019
0
Roche's Rituxan Gets Priority Review for Blood Disorder
http://www.zacks.com/stock/news/428757/roches-rituxan-gets-priority-review-for-blood-disorder?cid=CS-ZC-FT-428757
Jun 12, 2019 - Roche (RHHBY) gets Priority Review status from the FDA for Rituxan in children with two rare blood vessel disorders.
0
Novartis Reports Data on Cosentyx for Psoriatic Arthritis
http://www.zacks.com/stock/news/428752/novartis-reports-data-on-cosentyx-for-psoriatic-arthritis?cid=CS-ZC-FT-428752
Jun 12, 2019 - Novartis (NVS) announces new data on psoriatic arthritis drug, Cosentyx.
0
Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug
http://www.zacks.com/stock/news/427399/dr-reddys-reports-positive-top-line-data-on-psoriasis-drug?cid=CS-ZC-FT-427399
Jun 10, 2019 - Dr. Reddy's (RDY) reports positive top-line results from the phase IIb study on PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.
0
Page 1>